Zai Lab has announced that its New Drug Application (NDA) for Augtyro (repotrectinib) has been greenlit by China’s National Medical Products Administration (NMPA) for use in the treatment of adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). Augtyro, an orally administered tyrosine kinase inhibitor (TKI) designed to inhibit specific kinases and […]